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Abstract 
Heart failure became a leading cause of mortality in the past decades with a progressively 
increasing prevalence. Its current therapy is restricted largely to the suppression of the 
sympathetic activity and the renin-angiotensin system in combination with diuretics. This 
restrictive strategy is due to the potential long term adverse effects of inotropic agents 
despite their effective influence on cardiac function when employed for short durations. 
Positive inotropes include inhibitors of the Na+/K+ pump, β-receptor agonists and 
phosphodiesterase inhibitors. Theoretically, Ca2+ sensitizers may also increase cardiac 
contractility without resulting in Ca2+ overload nevertheless their mechanism of action is 
frequently complicated by other pleiotropic effects. Recently a new positive inotropic 
agent, the myosin activator omecamtiv mecarbil has been developed. Omecamtiv 
mecarbil binds directly to β-myosin heavy chain and enhances cardiac contractility by 
increasing the number of the active force-generating cross-bridges, presumably without 
major off-target effects. This review focuses on recent in vivo and in vitro results 
obtained with omecamtiv mecarbil, and discusses its mechanism of action at a molecular 
level. Based on clinical data, omecamtiv mecarbil is a promising new tool in the 
treatment of systolic heart failure. 
 
Keywords: inotropic agents, calcium sensitizer, cardiac myosin activator, omecamtiv 
mecarbil, CK-1827452, cardiac contractility, heart failure. 
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Current therapeutic strategies against heart failure 
Heart failure is diagnosed when the heart is not able to provide the required amount of 
cardiac output. Heart failure can be categorized from several viewpoints, e.g.: systolic vs. 
diastolic, left vs. right heart, compensated vs. decompensated, and by well-defined criteria 
for its progression (Felker et al. 2003). Regarding the therapeutic implications, the 
sharpest difference is between the acute and the chronic forms of heart failure, since in 
the former case the pump function of the heart has to be effectively facilitated using 
inotropic agents, regardless of the potential long-term shortcomings, while in the latter 
case the strategy may be the opposite, i.e. suppression of the neurohormonal 
compensation may increase the life span and improve the quality of life (Bristow 2000; 
Middlekauff and Mark 1998). 
In spite of the relative therapeutic success in the field of chronic heart failure in the past 
decades, little progress is seen in the treatment of acute heart failure. The potential 
positive inotropic strategies are displayed in Fig. 1. The first agents being applied to 
improve cardiac performance were digitalis glycosides. These agents suppress the 
activity of the Na+/K+ pump in the surface membrane resulting in a reduced 
transmembrane Na+ gradient, which in turn leads to cellular Ca2+ overload via the 
Na+/Ca2+ exchange (Altamirano et al. 2006; Lee 1985). In spite of the beneficial acute 
effects of these glycosides, long term improvement of contractility has been questioned 
(The Digitalis Investigation Group 1997), and more importantly, they displayed a 
significant proarrhythmic activity due to the possibility of Ca2+ overload. Indeed, 
development of delayed afterdepolarizations has frequently been reported in digitalis-
intoxicated patients (January and Fozzard 1988; Kass et al. 1978). 
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Positive inotropic action can be evoked by activation of the cardiac β-adrenergic 
receptors, since this is the natural way to increase the cardiac output through an increase 
in heart rate, positive inotropy and lusitropy. Ca2+ entry into the cardiomyocytes is 
strongly enhanced by the prtotein kinase A-dependent phosphorylation of L-type Ca2+ 
channes (Kamp and Hell 2000; Van der Heyden et al. 2005). The increased rate of Ca2+ 
sequestration into the SR, due to phosphorylation of phospholamban by protein kinase A 
is also crucial, since it results in reduction of diastolic but elevation of systolic Ca2+ 
concentration due to the increased Ca2+ content of the SR in addition to the positive effect 
of synchronization of SR Ca2+ release by β-adrenergic stimulation (Frank and Kranias 
2000; Song et al. 2001). 
Unfortunately, sympathomimetic agents are also strongly proarrhythmic due to 
several reasons. First of all, intracellular Ca2+ concentration is increased, which may 
generate delayed afterdepolarizations (Fozzard 1992; Tweedie et al. 2000). Furthermore, 
early afterdepolarizations manifested in torsade de pointes type serious cardiac 
arrhythmias are also generated by β-adrenergic activators under in vitro as well as in vivo 
conditions (January and Riddle 1990; Priori and Corr 1990). This is why β1-receptors are 
better to be suppressed than activated at longer time scale. Secondly, β-adrenergic 
activation increases myocardial oxygen consumption, which is unfavorable for the failing 
heart (Neubauer et al. 1994). However, selective activation of β3-adrenergic receptors, 
acting through the NO/cGMP pathway, may diminish the unfavorable consequences of 
cardiac remodeling, and thus may be useful in treatment of heart failure (Belge et al. 
2014). 
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 5
 Similarly to β-adrenergic activation, inhibition of the phosphodiesterase enzyme 
is also a suitable tool to increase the contractile force, since the cAMP level can be 
increased either by increased production or decreased demolition of cAMP. Amrinone 
and milrinone were the first molecules applied as positive inotropes acting by PDE 
inhibition (Honerjäger 1989). However, there are two major problems with this strategy. 
The first is largely identical with the application of β-adrenergic agonists, i.e. the 
resultant Ca2+ overload increases arrhythmia propensity (Fozzard 1992; Priori and Corr 
1990). Secondly, since cardiomyocytes may contain several phosphodiesterase 
isoenzymes, each having its characteristic signal transduction pathway and 
compartmentalization profile, selective inhibition of one single isoenzyme is possibly 
required (Steinberg and Brunton 2001; Takimoto et al. 2007; Vandecasteele et al. 2006). 
Suppression of the PDE-III isoform was widely used in heart failure with variable 
success. 
 In addition to the increased arrhythmia propensity due the resultant Ca2+ overload, 
common problem with β-adrenergic agonists and PDE inhibitors is that they increase the 
ATP utilization of working myocardium. This is because of the increased rate of Ca2+ 
cycling, i.e. more Ca2+ has to be actively removed from the cytoplasm under these 
conditions within a certain period of time. This may be unfavorable in chronic heart 
failure, since the failing heart is in poor metabolic conditions (Ardehali et al. 2012). 
Recently a new strategy of “RyR2 stabilization” has emerged. This is based on the fact 
that in some forms of heart failure the RyR2 is leaky allowing Ca
2+ to leak out of the SR 
during diastole (Shannon and Lew 2009; Wehrens and Marks 2003). This strongly 
deteriorates the pump function because of the increased diastolic Ca2+ level (diastolic 
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failure) combined with the reduced SR Ca2+ content (systolic failure). Ryanodine receptor 
stabilizers - by suppressing this diastolic leak - are believed to improve the contractile 
performance and reduce the energy demand of the heart (Ezekowitz 2013; Kaneko 1994). 
 An alternative approach of inotropic strategy is to increase the “efficacy” of the 
Ca2+ signal, i.e. more force to be generated by a given rise of cytosolic Ca2+, or less Ca2+ 
should be enough to generate a certain level of force (Endoh 2001). Increasing the 
affinity of troponin C to Ca2+, Ca2+ sensitizers improve the mechanical performance of 
the myocardium without increasing markedly its oxygen demand (Follath 2009; Lehmann 
et al. 2003). Since - at least theoretically - Ca2+ cycling is not enhanced, intracellular Ca2+ 
level and the concomitant arrhythmia incidence should not be elevated either (Endoh 
2008). Pimobendan and levosimendan, the best known representatives of conventional 
Ca2+ sensitizers, display also PDE inhibitory actions (Endoh 2002). Theoretically, the 
combination of Ca2+ sensitizer and PDE inhibitory effects may be clinically beneficial 
due to a PDE dependent counteraction of a predictable diastolic dysfunction caused by 
pure Ca2+ sensitization (Endoh 2001). The hemodynamic effects of levosimendan are 
further complicated as this drug opens ATP-sensitive K+ channels in vascular smooth 
muscle cells resulting in vasodilation (Papp et al. 2012). Furthermore, activation of these 
channels located in the mitochondrial membrane has been shown to display 
cardioprotective effects (Papp et al. 2012). Collectively, all the above mechanisms are 
likely to contribute to the therapeutic effects of levosimendan. The term positive inotropy 
with a “downstream mechanism” of action refers to a special way of Ca2+ sensitization, 
i.e. when myocardial systolic force is enhanced the modifications of the molecular events 
of the actin-myosin cycle directly (Endoh 2008). 
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Myosin activators - new strategy for increasing contractility 
As it was shown in the previous chapter, each of the known inotropic strategies suffers 
from more or less drawbacks. The ideal inotropic agent is expected (1) to enhance cardiac 
contractility selectively (i.e. having positive inotropic and lusitropic actions without 
chronotropic, dromotropic or bathmotropic responses), (2) not to increase the energy 
demand of the heart, and most importantly (3) not to increase arrhythmia propensity 
(Campia et al. 2010). It is also useful if its positive inotropic action is augmented under 
pathological conditions, e.g. in a failing heart. Since these goals could not be fully 
achieved by interventions acting upstream to the Ca2+-troponin binding, the research 
began to focus on the downstream steps. Ca2+ binding to troponin C engages a set of 
protein-protein interactions resulting finally in force generation. Indeed, interactions with 
these steps may provide several options to regulate contractility (Solaro 2009; Solaro 
2010; Sun et al. 2008). Probably the best of these strategies may be the application of 
myosin activators which increase the force of contraction by interacting directly with the 
myosin heavy chain, as omecamtiv mecarbil, the first selective cardiac myosin activator, 
does (Morgan et al. 2010). 
The first molecule screened out for increasing the ATPase activity of myosin was 
CK-0156636. Substitution of the nitrate group for fluorine in CK-1032100 improved the 
water solubility of the molecule diminishing this way the binding to plasma proteins. CK-
1122534 was the fist agent to increase the fractional shortening in rat ventricular 
myocardium, however, the ATP-sensitive K+ channels were also activated by the 
compound. CK-1213296 was free of this effect, but inhibited the CYP 1A2 enzyme. All 
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 8
side-effects were successfully eliminated from CK-1317138, and the optimized structure 
was achieved by CK-1827452, omecamtiv mecarbil (Morgan et al. 2010). This latter 
molecule was more potent by one order of magnitude than its ancestor, CK-1317138 
(Malik and Morgan 2011). 
 
In vitro and in vivo effects of omecamtiv mecarbil 
Omecamtiv mecarbil displays its positive inotropic effect by selective binding to the S1 
domain of the cardiac β-myosin heavy chain where the relay helix and converter domain 
converge at the base of the force-producing lever arm. Binding of omecamtiv mecarbil to 
this site results in a conformational change in the nucleotide-binding domain of the 
myosin head contributing to the allosteric activation of its enzymatic and mechanical 
properties (Malik and Morgan 2011). As a consequence of allosteric modulation of the 
nucleotide-binding domain of myosin, omecamtiv mecarbil was shown to accelerate the 
release of inorganic phosphate, which is the rate-limiting step of the actomyosin cycle, 
due to the increased ATPase activity of the myosin heavy chain, thereby accelerating the 
transition rate from the weakly bound to the strongly bound configuration of actin 
associated myosin heads by decreasing the energy barrier between them (Malik et al. 
2011). This effect results in an increased number of force-generating cross-bridges within 
the sarcomere and associated with the enhancement of force generation (Malik et al. 
2011; Teerlink 2009). Experiments performed in heterologously reconstituted 
combinations of actin-myosin systems revealed that the stimulation of ATPase by 
omecamtiv mecarbil occurs exclusively in the presence of the cardiac and slow skeletal 
muscle myosin isoforms (α, β) independently of the origin of the thin filament. Healthy 
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human hearts contain dominantly the β and to a lesser extent the α isoform, while α 
isoform practically disappears from the failing heart. Myosins from fast skeletal or 
smooth muscles are not activated by omecamtiv mecarbil suggesting a “quasi” 
cardiospecific binding of the drug (Leinwand and Moss 2011; Malik et al. 2011; Teerlink 
2009). In fact, omecamtiv mecarbil was shown to increase the contractility in slow 
skeletal muscle fibers (e.g. diaphragm) which may widen the potential therapeutic 
spectrum of the agent (Nagy et al. 2015). Omecamtiv mecarbil, in line with stabilization 
of the “strongly bound” configuration of myosin heads, reduced unloaded shortening 
velocity of porcine and human ventricular myosins when monitored by an in vitro 
mobility assay (Aksel et al. 2015; Liu et al. 2015; Wang et al. 2014). Since this effect was 
equally observed with α and β isoforms (Aksel et al. 2015), both atrial and ventricular 
contractility can readily be improved by omecamtiv mecarbil. 
Increasing the ATPase activity of the myosin heads is expected to increase cardiac 
oxygen consumption. Since omecamtiv mecarbil fails to increase (actually decreases) the 
actin-independent release of inorganic phosphate, the overall oxygen consumption of the 
heart is not expected to increase by the drug (Teerlink 2009). In absence of the extra 
energy demand related to an enhanced Ca2+ cycling, cardiac energy utilization can be 
more effective in the presence of omecamtiv mecarbil (Shen et al. 2010). Moreover, the 
mammalian heart is apparently robust enough to tolerate myosin motor tuning during 
long term administrations (James and Robbins 2011). Transgenic rabbits containing α 
and β isoforms of myosin at a ratio of 1:1 failed to show symptoms of cardiomyopathy, 
they were rather cardioprotected in an overdrive-induced heart failure model (James et al. 
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2005). In addition, the lifespan of these transgenic animals was similar to their normal 
littermates (James and Robbins 2011). 
Experiments studying the effects of omecamtiv mecarbil at a cellular level 
revealed the enhancement the fractional shortening in isolated rat cardiomyocytes without 
any alterations in the Ca2+ handling monitored by fluorescent Ca2+ indicators. 
Importantly, myosin activation resulted in an increase in both the amplitude and the 
duration of contractions (Malik et al. 2011). Omecamtiv mecarbil was also effective 
under in vivo conditions when the fractional shortening was monitored by 
echocardiography in anesthetized dogs and rats. Interestingly, canine hearts were more 
sensitive to omecamtiv mecarbil than rat hearts (Malik et al. 2011). 
In an in vivo canine model of pacing-induced systolic heart failure after 
myocardial infarction or chronic pressure overload, omecamtiv mecarbil infusion was 
shown to enhance left ventricular stroke volume, cardiac output and systolic ejection time 
in addition to reduction of heart rate, total peripheral resistance and loading pressures 
(Shen et al. 2010; Teerlink 2009). On the other hand, myocardial O2 consumption and the 
rate of pressure development were not affected by the drug when compared with 
traditional inotropes (Shen et al. 2010). Furthermore, omecamtiv mecarbil produced 
larger augmentation of the systolic performance in failing canine hearts than in healthy 
animals (Shen et al. 2010). In contrast to other inotropic agents, including 
catecholamines, the inotropic action of omecamtiv mecarbil was enhanced at longer 
while reduced at shorter pacing cycle lengths in unloaded canine cardiomyocytes (Butler 
et al. 2015). 
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It is important to bear in mind that any increase in the systolic ejection time may 
be displayed only at the expense of diastole, impeding thereby the ventricular filling as 
well as the coronary flow. However, since intravenous administration of omecamtiv 
mecarbil was reported to decrease heart rate, moderate improvements of systolic 
emptying should not dramatically compromise diastolic function or coronary flow 
(Dickstein 2011; Nagy et al. 2014). 
 Surprisingly, no cellular electrophysiological results have been reported with 
omecamtiv mecarbil so far. However, accordingly to our preliminary unpublished results, 
relatively high (10 µM) concentration of omecamtiv mecarbil caused small but 
statistically significant changes in canine ventricular action potential configuration as 
demonstrated in Fig. 2. These changes included the reduction of phase-1 repolarization, 
suppression of the plateau amplitude and shortening of action potential duration. 
Although regarding the involvement of the underlying ion currents we can only speculate 
in absence of relevant voltage clamp data, the smaller phase-1 amplitude indicates a 
reduction of the transient outward current (Ito), while depression of the plateau potential 
is congruent with a decreased L-type Ca2+ current. Clearly, further electrophysiological 
studies are required to map all possible effects of omecamtiv mecarbil on cardiac ion 
currents, since even relatively small shifts in these currents may be proarrhythmic in 
certain groups of sensitive patients. 
 
Clinical trials 
Based on promising preclinical results obtained with the myosin activator omecamtiv 
mecarbil (Meijs 2012), the drug was tested in a phase I study (Teerlink et al. 2011). The 
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primary goal was to determine the maximum-tolerated dose and plasma concentrations of 
the drug applied intravenously for a period of 6 hours, once a week for 4 weeks in 34 
healthy volunteers. The secondary goal was the evaluation of pharmacodynamic 
properties of the effects on left ventricular systolic function assessed by transthoracic 
echocardiography, safety and tolerability (Teerlink et al. 2011). In this first-in-men dose-
escalating study, omecamtiv mecarbil was shown to effectively enhance left ventricular 
systolic function in a dose-dependent manner applying doses of 0.005–1 mg/kg/h. Within 
this range a linear dose-related correlation was found between the plasma concentrations 
and systolic ejection time. Improvement of the systolic performance of the heart was not 
associated with impairment of diastolic function. The maximum-tolerated dose was 0.5 
mg/kg/h; no adverse effect was observed at this concentration. The dose-limiting toxic 
effect was myocardial ischemia due to the prolongation of the systolic ejection time at the 
expense of diastole (Teerlink 2009; Teerlink et al. 2009; Teerlink et al. 2011). 
A double-blind, randomized, placebo-controlled, dose-ranging phase II trial was 
performed in 45 patients with stable heart failure and left ventricular systolic dysfunction 
treated with ACE inhibitor (Cleland et al. 2011). The primary aim was to study the safety 
and tolerability of the drug in this group of patients, who received omecamtiv mecarbil 
infusion for 2, 24, or 72 hours. Omecamtiv mecarbil increased left ventricular ejection 
time by up to 80 ms from the baseline value, while stroke volume was increased by up to 
9.7 ml. These changes were accompanied by reduction of heart rate by up to 2.7 
beats/min. Higher plasma concentrations resulted a decrease in end-systolic and end-
diastolic volumes by 15 and 16 ml, respectively (Cleland et al. 2011). Comparing these 
results to those obtained from phase I trial, it can be concluded that beneficial effects of 
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omecamtiv mecarbil are comparable in healthy individuals and heart failure patients. The 
well-tolerated plasma concentration was within the range of 0.1-1.2 µg/ml. At higher 
plasma levels (1.35 and 1.75 µg/ml), however, two patients complained for consequences 
of myocardial ischemia due to the excessive prolongation of systolic ejection time 
(Cleland et al. 2011). 
A randomized, controlled phase IIb trial was performed to evaluate the safety and 
efficacy of omecamtiv mecarbil in patients suffering from acute heart failure (ATOMIC-
AHF, 2014). This study revealed that the omecamtiv mecarbil-induced myosin activation 
failed to meet the primary end point since no significant effect on dyspnea could be 
demonstrated. It was finally concluded that the administration of omecamtiv mecarbil is 
clinically safe, and the results showed a tendency of slowing the progression of heart 
failure (ATOMIC-AHF, 2014; Garg and Frishman 2013; Valentova and von Haehling 
2014). 
Recently, omecamtiv mecarbil was studied in a set of patients hospitalized with 
cardiomyopathy combined with ischemic heart disease (angina pectoris) in order to 
monitor the safety and tolerability of the agent in ischemic cardiomyopathies (Greenberg 
et al. 2015). This combination was critically important, since myocardial ischemia due to 
the excessive prolongation of systolic ejection time has already been observed in case of 
overdose. In this double-blind, placebo-controlled study the effect of 20 hours infusion 
with omecamtiv mecarbil was evaluated on the cardiac performance during a treadmill 
test. The results indicate that omecamtiv mecarbil at doses producing plasma 
concentrations sufficient to effectively increase systolic function is well tolerated during 
physical exercise even in patients with ischemic cardiomyopathy and angina (Greenberg 
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et al. 2015). Since at higher concentrations (i.e. in case of overdose intoxication) these 
ischemic consequences may really be anticipated, extra caution has to be applied with the 
dosage of omecamtiv mecarbil due to the unknown magnitude of interpersonal 
differences in drug-sensitivity and pharmacokinetics. 
Data from 3 clinical trials with omecamtiv mecarbil were analyzed using a 
nonlinear mixed-effects model to investigate pharmacokinetic properties of the drug and 
the relationship between plasma concentration and left ventricular outflow tract stroke 
volume and systolic ejection time (Vu et al. 2015). Oral absorption half-life of the drug 
was 0.62 hour and absolute bioavailability was estimated as 90%, while the elimination 
half-life was 18.5 hour. Plasma concentrations were directly correlated with increases in 
stroke volume and ejection time in healthy volunteers as well as in patients with heart 
failure. Model-based simulations for several immediate-release oral dose regimens (37.5, 
50 and 62.5 mg doses every 8, 12 and 24 hours) showed that a pharmacodynamic effect 
could be maintained in the absence of excessive omecamtiv mecarbil plasma 
concentrations (Vu et al. 2015). 
Taken all data together, omecamtiv mecarbil seems to be a very promising 
approach for the treatment of systolic heart failure indicating that the strategy of myosin 
activation may be effectively translated into the clinical practice (Nagy et al. 2014). 
 
Perspectives 
In light of the results discussed above the group of Ca2+ sensitizer agents provides the 
most suitable therapy for both acute and chronic heart failure - at least according to our 
present knowledge. The conventional approach of increasing the Ca2+ cycling in 
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myocytes was not supported by positive therapeutic experience. The reasons are clearly 
the increased energy consumption and arrhythmia propensity. Ca2+ sensitizers - 
theoretically - should be free of these side-effects. In case of acute heart failure Ca2+ 
sensitizers alone may probably be the main-stream therapy in the future. In chronic heart 
failure application of these drugs, in combination with the conventional β-blocker + ACE 
inhibitor + diuretic therapy, gives a chance to the “pharmacologically suppressed” heart 
to enhance its mechanical performance, which may significantly improve the quality of 
life of the patients. Since omecamtiv mecarbil can be considered as a representative of a 
novel group of Ca2+ sensitizers, the question whether conventional Ca2+ sensitizers or 
myosin activators will provide better therapeutic results has to be answered with no doubt 
(Spinarova and Spinar 2015). Further clinical and preclinical studies are required to 
reveal and to discriminate between their potential effects on cardiac oxygen consumption 
and cardiac rhythm during various cardiac pathologies (Givertz et al. 2013; Hasenfuss 
and Teerlink 2011; Kehat 2012; Rajapreyar et al. 2014; Selby and Teerlink 2013; Tarone 
et al. 2014). Properly designed clinical trials will hopefully also help to reach final 
conclusions. The most dangerous potential pitfall with omecamtiv mecarbil may be the 
compromised diastolic filling (Bers and Harris 2011) which is not compensated by 
suppressed PDE activity as in the case of other Ca2+ sensitizers. 
 As previously mentioned, no change in intracellular Ca2+ transients was observed 
with omecamtiv mecarbil in ventricular myocytes of the rat (Malik et al. 2011). This was 
considered as a strong argument supporting the pure “downstream” mechanism of action 
of the drug (i.e. the lack of action on Ca2+ release and Ca2+ reuptake). Unfortunately, the 
rat is not an ideal experimental model from this point of view, because neither 
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electrophysiological properties, nor the Ca2+ handling in rat is similar to that found in 
larger mammals including humans. This doubt can easily be eliminated by testing 
omecamtiv mecarbil on Ca2+ handling in larger mammals. 
 The cardioselective nature of the action of omecamtiv mecarbil is usually 
mentioned as an advantage, since myosins from fast skeletal and smooth muscles are not 
affected. However, the potential therapeutic benefits of omecamtiv mecarbil, related to 
facilitation of slow skeletal muscle contractility, cannot be overemphasized (Bers and 
Harris 2011; Leinwand and Moss 2011; Nagy et al. 2015). Slow-twitch skeletal muscles, 
such as the diaphragm, are equipped with a set of myosins similar to that found in the 
heart. Therefore omecamtiv mecarbil is likely to improve the mechanical performance of 
the diaphragm (and other slow-twitch muscles in the body), which may be important for 
patients on ventilators or healthy individuals in elderly (Bers and Harris 2011). In support 
of this idea omecamtiv mecarbil was shown to facilitate contractility in rat diaphragm 
similarly to cardiac myocytes. These experiments clearly indicated the Ca2+ sensitizer 
properties of omecamtiv mecarbil based on slowing the activation-relaxation kinetics 
(Nagy et al. 2015). 
 Since omecamtiv mecarbil is selectively bound to cardiac myosins, it can be used 
for labeling in order to visualize the myosin heads in the heart. Indeed, 18F-labeled 
analogues of omecamtiv mecarbil were applied for cardiac myosin imaging under 
conditions of positron emission tomography (Zhang et al. 2013). This technique - when 
combined with sarcomere length nanometry (Shintani et al. 2014) - may give a new 
insight into the mechanics of the contractile machinery. 
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Figure legends 
 
Fig. 1.  Ca2+ handling and positive inotropic straregies in the heart. Red arrows indicate 
transmembrane and intracellular Ca2+ movements, including the L-type Ca2+ channel, 
sarcolemmal Ca2+ pump, Na+/Ca2+ exchanger, RyR2 receptor and SERCA pump. Blue 
arrows show sites of possible inotropic interventions (see details in the text). 
 
Fig. 2.  Effects of omecamtiv mecarbil in enzymatically isolated canine ventricular 
myocytes. A: Representative superimposed action potentials recorded at 37 oC using a 
sharp 3M KCl-containing microelectrode in Tyrode solution (Control), after superfusion 
with 10 µM omecamtiv mecarbil (OM) for 10 min, and following the washout of the 
drug. B: Average results obtained with 10 µM omecamtiv mecarbil in 14 canine 
ventricular cells. Phase-1 amplitude was defined as a difference between overshoot 
potential and voltage of the notch. Plateau amplitude vas measured as the amplitude of 
the plateau (the actual membrane potential minus resting potential) obtained at the time of 
50% repolarization. Action potential duration was determined at 90% level of 
repolarization. Columns and bars indicate mean ± SEM values, respectively, asterisks 
denote significant (P<0.05) changes from control. C: Time course of development of 
drug-effects and their partial elimination upon washout. 
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